Alivium® is developed by Pfizer.

What development phase is Alivium® in?

Alivium® is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Alivium®

Pfizer · FDA-approved active Small molecule Quality 0/100

At a glance

Generic name	Alivium®
Also known as	Group 2
Sponsor	Pfizer
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Extract of Curcuma Longa Complexed With Phosphatidilcholine(Motore®)in the Treatment of Adults With Knee Osteoarthritis (PHASE4)
A Relative BioavailabilityStudy Of Ibuprofen 40mg/ml (laboratórios Pfizer Ltda) In The Oral Suspension Form. (PHASE4)
A Bioequivalence Study Of Ibuprofen 50mg/ml (laboratórios Pfizer Ltda) In The Oral Suspension Form. (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Alivium® CI brief — competitive landscape report
Alivium® updates RSS · CI watch RSS
Pfizer portfolio CI